Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cander Patients - AGMT_GASTRIC-3

Ewald Wöll; Josef Thaler; Felix Keil; Birgit Gruenberger; Michael Hejna; Wolfgang Eisterer; Michael Fridrik; Hanno Ulmer; Vera Trommet; Florian Huemer; Lukas Weiss; Richard Greil

doi:10.21873/anticanres.11987

Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cander Patients - AGMT_GASTRIC-3

Ewald Wöll, Josef Thaler, Felix Keil, Birgit Gruenberger, Michael Hejna, Wolfgang Eisterer, Michael Fridrik, Hanno Ulmer, Vera Trommet, Florian Huemer, Lukas Weiss, Richard Greil

Faculty of Medicine

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	5553-5558
Number of pages	6
Journal	Anticancer Research
Volume	37
Issue number	10
DOIs	https://doi.org/10.21873/anticanres.11987
Publication status	Published - 2017

Fields of science

302 Clinical Medicine

JKU Focus areas

Medical Sciences (in general)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/anticanres.11987

Cite this

Wöll, E., Thaler, J., Keil, F., Gruenberger, B., Hejna, M., Eisterer, W., Fridrik, M., Ulmer, H., Trommet, V., Huemer, F., Weiss, L., & Greil, R. (2017). Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cander Patients - AGMT_GASTRIC-3. Anticancer Research, 37(10), 5553-5558. https://doi.org/10.21873/anticanres.11987

@article{c4512fa6ac3548d9b43a7a3d654077b2,

title = "Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cander Patients - AGMT\_GASTRIC-3",

author = "Ewald W{\"o}ll and Josef Thaler and Felix Keil and Birgit Gruenberger and Michael Hejna and Wolfgang Eisterer and Michael Fridrik and Hanno Ulmer and Vera Trommet and Florian Huemer and Lukas Weiss and Richard Greil",

year = "2017",

doi = "10.21873/anticanres.11987",

language = "English",

volume = "37",

pages = "5553--5558",

journal = "Anticancer Research",

issn = "1791-7530",

number = "10",

}

Wöll, E, Thaler, J, Keil, F, Gruenberger, B, Hejna, M, Eisterer, W, Fridrik, M, Ulmer, H, Trommet, V, Huemer, F, Weiss, L & Greil, R 2017, 'Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cander Patients - AGMT_GASTRIC-3', Anticancer Research, vol. 37, no. 10, pp. 5553-5558. https://doi.org/10.21873/anticanres.11987

TY - JOUR

T1 - Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cander Patients - AGMT_GASTRIC-3

AU - Wöll, Ewald

AU - Thaler, Josef

AU - Keil, Felix

AU - Gruenberger, Birgit

AU - Hejna, Michael

AU - Eisterer, Wolfgang

AU - Fridrik, Michael

AU - Ulmer, Hanno

AU - Trommet, Vera

AU - Huemer, Florian

AU - Weiss, Lukas

AU - Greil, Richard

PY - 2017

Y1 - 2017

UR - https://www.ncbi.nlm.nih.gov/pubmed/28982869

U2 - 10.21873/anticanres.11987

DO - 10.21873/anticanres.11987

M3 - Article

SN - 1791-7530

VL - 37

SP - 5553

EP - 5558

JO - Anticancer Research

JF - Anticancer Research

IS - 10

ER -

Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cander Patients - AGMT_GASTRIC-3

Fields of science

JKU Focus areas

UN SDGs

Access to Document

Other files and links

Cite this